Johnson & Johnson's Q2 knee sales tumble 50% in the US — 6 earnings insights

Angie Stewart -   Print  |

Johnson & Johnson's second-quarter orthopedic sales in the U.S. were down 34.7 percent year over year, at $869 million.

Six insights on the company's second-quarter earnings:

1. With $583 million in orthopedic sales abroad, Johnson & Johnson reported total worldwide orthopedic sales revenue of $1.45 billion. This represented a 34.7 percent decrease from the same period in 2019.

2. The company's hip offerings generated $137 million in U.S. sales and $88 million in international sales, representing year-over-year decreases of 36.5 percent and 39.8 percent, respectively.

3. Johnson & Johnson's knee business generated $108 million in U.S. sales, down 50.5 percent from $218 million in the second quarter of 2019. International knee sales had an even bigger fall, from $153 million in the second quarter of 2019 to $66 million this most recent quarter.

4. For its "spine, sports and other" business, Johnson & Johnson reported $270 million in U.S. sales and $230 million in international sales, representing respective year-over-year decreases of 45 percent and 29.9 percent.

5. Johnson & Johnson's trauma business had the lowest year-over-year decline of any line, when compared on worldwide sales. Trauma worldwide sales were down 17.8 percent to $553 million. U.S. sales were down 12.9 percent to $354 million, and international sales decreased 25.2 percent to $198 million.

6. Worldwide medical device sales of $4.3 billion represented a 33.9 percent decline from the second quarter of 2019.

More articles on devices:
7D Surgical radiation-free spine surgery system gets European approval
Medtronic to buy Medicrea for 22% above share price: 6 details
2 hospitals with new spine surgery programs

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers